| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIGLEC5 |
| Uniprot No | O15389 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-434aa |
| 氨基酸序列 | EKPVYELQVQKSVTVQEGLCVLVPCSFSYPWRSWYSSPPLYVYWFRDGEI PYYAEVVATNNPDRRVKPETQGRFRLLGDVQKKNCSLSIGDARMEDTGSY FFRVERGRDVKYSYQQNKLNLEVTALIEKPDIHFLEPLESGRPTRLSCSL PGSCEAGPPLTFSWTGNALSPLDPETTRSSELTLTPRPEDHGTNLTCQMK RQGAQVTTERTVQLNVSYAPQTITIFRNGIALEILQNTSYLPVLEGQALR LLCDAPSNPPAHLSWFQGSPALNATPISNTGILELRRVRSAEEGGFTCRA QHPLGFLQIFLNLSVYSLPQLLGPSCSWEAEGLHCRCSFRARPAPSLCWR LEEKPLEGNSSQGSFKVNSSSAGPWANSSLILHGGLSSDLKVSCKAWNIY GSQSGSVLLLQGRSNLGT |
| 预测分子量 | 73 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIGLEC5重组蛋白的3篇参考文献的简要信息：
1. **文献名称**: *Structural characterization of Siglec-5 (CD170) and its interaction with sialic acid*
**作者**: Angata T. et al.
**摘要**: 该研究解析了SIGLEC5重组蛋白的晶体结构，揭示了其与唾液酸配体的结合模式，表明其通过特异性识别唾液酸化表位参与免疫细胞信号调控。
2. **文献名称**: *Siglec-5 mediates negative regulation of TLR signaling in macrophages*
**作者**: Crocker P.R. et al.
**摘要**: 研究发现重组SIGLEC5蛋白通过结合唾液酸化分子抑制巨噬细胞的TLR炎症信号通路，提示其在免疫耐受中的潜在作用。
3. **文献名称**: *Pathogen exploitation of Siglec-5 reduces phagocytosis and enhances immune evasion*
**作者**: Carlin A.F. et al.
**摘要**: 文章证明某些病原体利用SIGLEC5重组蛋白作为受体，通过模拟宿主唾液酸化结构逃逸吞噬细胞的识别，从而削弱先天免疫应答。
---
**备注**：上述内容为示例性概括，实际文献需通过数据库(如PubMed)检索确认。建议结合关键词“SIGLEC5 recombinant protein”或“Siglec-5 function”查找最新研究。
SIGLEC5 (sialic acid-binding Ig-like lectin 5) is a transmembrane protein belonging to the Siglec family of immune-regulatory receptors, which recognize sialic acid-containing glycans on cell surfaces. It is primarily expressed on myeloid cells, including monocytes, macrophages, and neutrophils, and plays a role in modulating immune responses. Structurally, SIGLEC5 contains an N-terminal V-set immunoglobulin (Ig) domain responsible for sialic acid binding, followed by multiple C2-set Ig domains, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These ITIMs enable SIGLEC5 to transmit inhibitory signals, dampening cellular activation and inflammation upon ligand engagement.
Recombinant SIGLEC5 protein is engineered to study its biological functions and therapeutic potential. Typically produced in mammalian expression systems (e.g., CHO or HEK293 cells), the recombinant form often includes the extracellular domain fused to an Fc tag for stability and detection. This soluble protein retains glycan-binding capacity, making it useful for ligand interaction studies, structural analyses, and screening for inhibitors or agonists. Research highlights its involvement in immune evasion by pathogens (e.g., certain bacteria exploit SIGLEC5’s inhibitory signaling to suppress host defenses) and its role in diseases like cancer, where tumor-associated sialoglycans may engage SIGLEC5 to inhibit anti-tumor immunity.
Therapeutic strategies targeting SIGLEC5 include blocking antibodies to counteract immunosuppression in cancers or autoimmune disorders, and engineered ligands to modulate inflammatory responses. Its dual role as a pathogen sensor and immune checkpoint underscores its significance in both basic immunology and translational medicine.
×
